Dermira (DERM) Rating Increased to Buy at BidaskClub

Dermira (NASDAQ:DERM) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Friday.

A number of other analysts have also issued reports on the company. Cantor Fitzgerald restated a “buy” rating and issued a $20.00 target price on shares of Dermira in a report on Wednesday, September 5th. Zacks Investment Research lowered Dermira from a “hold” rating to a “sell” rating in a report on Monday, August 13th. Finally, Needham & Company LLC set a $16.00 price objective on Dermira and gave the stock a “buy” rating in a report on Friday, May 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $27.00.

DERM opened at $10.57 on Friday. Dermira has a 12-month low of $6.98 and a 12-month high of $31.42. The company has a quick ratio of 4.78, a current ratio of 4.78 and a debt-to-equity ratio of 2.49.

Dermira (NASDAQ:DERM) last released its earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.57). The company had revenue of $39.08 million during the quarter, compared to analyst estimates of $39.00 million. Dermira had a negative return on equity of 128.21% and a negative net margin of 761.87%. equities research analysts predict that Dermira will post -5.46 EPS for the current year.

In other news, CEO Thomas G. Wiggans acquired 11,875 shares of the business’s stock in a transaction that occurred on Monday, June 18th. The stock was acquired at an average cost of $10.10 per share, for a total transaction of $119,937.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders have purchased 49,805 shares of company stock valued at $479,517. 14.80% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in the stock. venBio Select Advisor LLC raised its holdings in shares of Dermira by 125.5% during the first quarter. venBio Select Advisor LLC now owns 3,427,378 shares of the biopharmaceutical company’s stock worth $27,385,000 after acquiring an additional 1,907,378 shares in the last quarter. Voya Investment Management LLC raised its holdings in Dermira by 7.5% during the second quarter. Voya Investment Management LLC now owns 1,197,773 shares of the biopharmaceutical company’s stock valued at $11,020,000 after buying an additional 83,064 shares in the last quarter. Orbimed Advisors LLC bought a new position in Dermira during the second quarter valued at about $9,491,000. Franklin Resources Inc. raised its holdings in Dermira by 13.5% during the first quarter. Franklin Resources Inc. now owns 1,013,100 shares of the biopharmaceutical company’s stock valued at $8,095,000 after buying an additional 120,600 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Dermira by 94.2% during the second quarter. Dimensional Fund Advisors LP now owns 621,928 shares of the biopharmaceutical company’s stock valued at $5,722,000 after buying an additional 301,690 shares in the last quarter. Institutional investors and hedge funds own 81.39% of the company’s stock.

About Dermira

Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.

Recommended Story: Growth Stocks

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply